We use essential cookies (authentication, your saved goals/stack) by default. With your permission we'll also enable privacy-respecting analytics (Vercel Web Analytics, anonymous load-time metrics) and error-replay diagnostics (Sentry — DOM snapshots only when an error fires) so we can fix bugs faster. Learn more about cookies
Afa5.0
Afamelanotide Research
Mostly mechanism / observationalLimited safety
10 peer-reviewed studies
What the evidence says
Mostly mechanism / observational
Most Afamelanotide studies are mechanism or observational rather than RCTs that measure a clinical effect — keep findings provisional.
Most evidence is from medium-quality randomised trials published 2010–2023 with a typical study size of 70 participants.
Based on 10 studies · 2 RCTs · 293 total participants
Confidence
Low
By outcome
Photoprotection & EPP
Mostly mechanism / observational8 studies
Safety & melanocytic risk
Mostly mechanism / observational5 studies
Skin pigmentation & vitiligo
Mostly mechanism / observational3 studies
Steady research
2 studies in the last 5 years
201020162023
1RCTn=168 · medium study2015
Afamelanotide... was associated with an increased duration of sun exposure without pain and improved quality of life in patients with erythropoietic protoporphyria.
Langendonk JG, Balwani M, Anderson KE, Bonkovsky HL, Anstey AV, Bissell DM, et al. · N Engl J Med (2015)
Two multicenter, randomized, double-blind, placebo-controlled Phase 3 trials of 16 mg subcutaneous afamelanotide implants every 60 days (EU n=74, US n=94)
Primary endpoint (pain-free hours of direct sunlight) was significantly longer with afamelanotide in both trials (US: 69.4 vs 40.8 h, P=0.04; EU: 6.0 vs 0.8 h, P=0.005)
Fewer phototoxic reactions (EU: 77 vs 146, P=0.04) and improved quality of life in both trials
A combination of afamelanotide implant and NB-UV-B phototherapy resulted in clinically apparent, statistically significant superior and faster repigmentation compared with NB-UV-B monotherapy.
Lim HW, Grimes PE, Agbai O, Hamzavi I, Henderson M, Haddican M, Linkner RV, Lebwohl M. · JAMA Dermatol (2015)
Randomized multicenter trial in non-segmental vitiligo: combination 16 mg afamelanotide + NB-UV-B (n=28) vs NB-UV-B monotherapy (n=27)
Combination superior on Vitiligo Area Scoring Index and faster face/upper-extremity repigmentation
Repigmentation at day 168: 48.6% (combination) vs 33.3% (monotherapy)
In the phase III trial, CUV039, afamelanotide treatment improved light tolerance in patients with EPP... enabled patients to spend more time in direct sunlight without pain.
Kim ES, Garnock-Jones KP. · Am J Clin Dermatol (2016)
Drug review summarizing the approved 16 mg controlled-release subcutaneous implant for EPP
Confirmatory Phase 3 trial CUV039 increased pain-free sun-exposure time and time to first phototoxicity symptoms vs placebo
Generally well tolerated; no drug-related serious adverse events; common reactions headache and implant-site reactions
Afamelanotide binds to the melanocortin-1 receptor (MC1R), and MC1R signaling increases melanin synthesis, induces antioxidant activities, enhances DNA repair processes and modulates inflammation.
Minder EI, Barman-Aksoezen J, Schneider-Yin X. · Clin Pharmacokinet (2017)
Pharmacokinetic/pharmacodynamic review of the first α-MSH analogue and MC1R agonist
Subcutaneous route had full bioavailability; oral and transdermal produced no measurable levels or pigmentation
Controlled-release implant is effective at lower dose than daily injections; approved by EMA in 2014 for EPP phototoxicity
Increasing numbers of case reports indicate that the unregulated use of both melanotan I and II is associated with cutaneous complications, particularly melanocytic changes in existing moles and newly emerging (dysplastic) nevi.
Habbema L, Halk AB, Neumann M, Bergman W. · Int J Dermatol (2017)
Review of risks of unregulated α-MSH analogues (melanotan I and II) used for tanning
Contrasts these with afamelanotide, the only α-MSH analogue approved for limited medical indications and 'thoroughly tested and deemed safe'
Case reports link unregulated melanotan to melanocytic changes in moles and new dysplastic nevi; four reports describe melanomas emerging from existing moles
There is randomized controlled trial (RCT) evidence for the successful use of afamelanotide in several conditions beyond erythropoietic protoporphyria, including polymorphic light eruption and vitiligo.
Wu J, Cotliar R. · J Drugs Dermatol (2021)
Review of afamelanotide (Scenesse), FDA-approved to increase pain-free sunlight exposure in adults with EPP
Dual photoprotective and anti-inflammatory effects underpin interest in other photosensitive diseases
RCT evidence in polymorphic light eruption and vitiligo; smaller studies in acne, Hailey-Hailey disease and solar urticaria